Abstract: The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.
Type:
Application
Filed:
December 15, 2010
Publication date:
July 21, 2011
Applicant:
Abbott Biotherapeutics Corporation
Inventors:
Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
Abstract: This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8° C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.
Type:
Application
Filed:
November 24, 2010
Publication date:
March 24, 2011
Applicant:
Abbott Biotherapeutics Corporation
Inventors:
Elizabet A. Kaisheva, Supriya Gupta, Shanti G. Duvur, Malathy Subramanian